Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation

Liver Transplantation

Volumn 16, Issue 12, 2010, Pages 1386-1392

  Lladó, Laura ^a   Baliellas, Carme ^a   Casasnovas, Carlos ^a   Ferrer, Isidre ^a   Fabregat, Joan ^a   Ramos, Emilio ^a   Castellote, Jose ^a   Torras, Jaume ^a   Xiol, Xavier ^a   Rafecas, Antoni ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PREALBUMIN;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; AMYLOIDOSIS; ARTICLE; CARPAL TUNNEL SYNDROME; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; DOMINO LIVER TRANSPLANTATION; DYSESTHESIA; ELECTROMYOGRAPHY; ELECTRONEUROMYOGRAPHY; FAMILIAL AMYLOID POLYNEUROPATHY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; NERVE BIOPSY; NEUROLOGIC EXAMINATION; POLYNEUROPATHY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECTUM BIOPSY; SENSORIMOTOR NEUROPATHY; SURAL NERVE BIOPSY; SYSTEMIC TRANSTHYRETIN AMYLOIDOSIS;

AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; BIOPSY; CROSS-SECTIONAL STUDIES; ELECTROMYOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PREALBUMIN; RETROSPECTIVE STUDIES; RISK FACTORS; SURAL NERVE;

EID: 78649868618     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22174     Document Type: Article

References (30)

1. Andrade C., A peculiar form of peripheral neuropathy. Familial atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-427.
2. Sekijuma Y, Yoshida K, Tokuda T, Ikeda S., Familial transthyretin amyloidosis. In:, Pagon RA, Bird TC, Dolan CR, Stephens K, eds. Gene Reviews. Seattle, WA: University of Washington; 2005.
3. Holmgren G, Ericzon BG, Groth CG, Steen L, Suhr O, Andersen O, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
4. Adams D, Slama M, Samuel D., Liver transplantation for familial amyloid polyneuropathy [in French]. Presse Med 2010; 39: 17-25.
5. Furtado A, Tomé L, Oliveira FJ, Furtado E, Viana J, Perdigoto R., Sequential liver transplantation. Transplant Proc 1997; 29: 467-468.
6. Wilczek HE, Larsson M, Yamamoto S, Ericzon BG., Domino liver transplantation. J Hepatobiliary Pancreat Surg 2008; 15: 139-148.
7. Familial Amyloidotic Polyneuropathy World Transplant Registry and Domino Liver Transplant Registry. Accessed August 2010.
8. Azoulay D, Samuel D, Castaing D, Adam R, Adams D, Said G, Bismuth H., Domino liver transplants for metabolic disorders: experience with familial amyloidotic polyneuropathy. J Am Coll Surg 1999; 189: 584-593.
9. Stangou AJ, Heaton ND, Hawkins PN,. Transmission of systemic transthyretin amyloidosis by means of domino liver transplantation. N Engl J Med 2005; 352: 2356.
10. Goto T, Yamashita T, Ueda M, Ohshima S, Yoneyama K, Nakamura M, et al. Iatrogenic amyloid neuropathy in a Japanese patient after sequential liver transplantation. Am J Transplant 2006; 6: 2512-2515.
11. Barreiros AP, Geber C, Birklein F, Galle PR, Otto G., Clinical symptomatic de novo systemic transthyretin amyloidosis 9 years after domino liver transplantation. Liver Transpl 2010; 16: 109.
12. Ericzon BG,. Domino transplantation using livers from patients with familial amyloidotic polyneuropathy: should we halt? Liver Transpl 2007; 13: 185-187.
13. Samuel D, Adams D,. Domino liver transplantation from familial amyloidotic polyneuropathy donors: how close is the Damocles sword to the recipient? Transpl Int 2007; 20: 921-923.
14. Furtado AJ., Domino liver transplantation using FAP grafts. HUC experience-hopes and realities. Amyloid 2003; 10 (suppl 1): 84-87.
15. Bittencourt PL, Couto CA, Leitão RM, Siqueira SA, Farias AQ, Massarollo PC, Mies S,. No evidence of de novo amyloidosis in recipients of domino liver transplantation: 12 to 40 (mean 24) month follow-up. Amyloid 2002; 9: 194-196.
16. Sousa MM, Ferrão J, Fernandes R, Guimarães A, Geraldes JB, Perdigoto R, et al. Deposition and passage of transthyretin through the blood-nerve barrier in recipients of familial amyloid polyneuropathy livers. Lab Invest 2004; 84: 865-873.
17. Takei Y, Gono T, Yazaki M, Ikeda S, Ikegami T, Hashikura Y, et al. Transthyretin-derived amyloid deposition on the gastric mucosa in domino recipients of familial amyloid polyneuropathy liver. Liver Transpl 2007; 13: 215-218.
18. Yamamoto S, Wilczek HE, Iwata T, Larsson M, Gjertsen H, Söderdahl G, et al. Long-term consequences of domino liver transplantation using familial amyloidotic polyneuropathy grafts. Transpl Int 2007; 20: 926-933.
19. Adams D, Lacroix C, Antonini T, Lozeron P, Denier C, Epelbaum S, et al. Risk of developing de novo amyloid deposits and induced polyneuropathy in FAP domino liver recipients [abstract]. Eur J Neurol 2009; 16 (suppl 13): 16-54.
20. Sousa MM, Du Yan S, Fernandes R, Guimaraes A, Stern D, Saraiva MJ., Familial amyloid polyneuropathy: receptor for advanced glycation end-products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001; 21: 7576-7586.
21. Said G., Familial amyloid polyneuropathy: mechanisms leading to nerve degeneration. Amyloid 2003; 10 (suppl 1): 7-12.
22. Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, et al. Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients' survival. Liver Transpl 2009; 15: 1229-1335.
23. Koike H, Ando Y, Ueda M, Kawagashira Y, Iijima M, Fujitake J, et al. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. J Neurol Sci 2009; 287: 178-184.
24. Holmgren G, Costa PM, Andersson C, Asplund K, Steen L, Beckman L, et al. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994; 31: 351-354.
25. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellié C, Planté-Bordeneuve V., Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 2008; 15: 181-186.
26. Ikeda S, Nakazato M, Ando Y, Sobue G., Familial transthyretin-type amyloid polyneuropathy in Japan: clinical and genetic heterogeneity. Neurology 2002; 58: 1001-1007. (Pubitemid 34298536)
27. Amante MF, Trigo P, Lendoire J, Imventarza O, Parisi C., Transthyretin familial amyloidotic polyneuropathy: histopathological study of the explanted livers. Ann Hepatol 2003; 2: 171-174.
28. Miller SR, Sekijima Y, Kelly W., Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Lab Invest 2004; 84: 545-552.
29. Sekijima Y, Kelly JW, Ikeda S., Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidosis. Curr Pharm Des 2008; 14: 3219-3330.
30. Sekijima Y, Dendle MA, Kelly JW., Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236-249.